Summar-ErbB-2 and EGFR (epidermal growth factor receptor) are expressed in lung adenocarcinomas and associated with a poor prognosis. Immunocytochemical analysis revealed erbB-2 and EGFR coexpression as a characteristic feature of most lung adenocarcinomas, and at levels of receptor expression present in bronchial epithelial cells. In primary lung tumours and cell lines. erbB-2 detected using Western blot analysis demonstrated low-level phosphotyrosine staining of the 185 kDa band, as compared with breast cancer cell lines. A549 and A427 lung adenocarcinoma cells treated with neu differentiation factor (NDF) showed increased erbB-2 phosphotyrosine staining, but to a much lesser extent than breast cancer cells. The lung cells were examined for expression of the potential autocrine growth factors NDF and transforming growth factor m (TGF-a) by Northern blot analysis. Both NDF and TFG-a mRNA were abundantly expressed in the A549 cells. NDF mRNA was highest during active cell proliferation and decreased in confluent cells or after treatment with the growth-inhibitory steroid dexamethasone. Primary tumours and cell lines expressed EGFR. shoWing higher basal level phosphotyrosine staining than erbB-2. Treatment with NDF and EGF (epidermal growth factor) stimulated cell growth. and in A549 cells the presence of both factors provided an additive increase in cell growth. The growth stimulus that ligand-activated erbB-2 and EGFR provides to lung adenocarcinoma cells may establish a background of continued cell proliferation over which other critical transforming events may occur.
ErbB-2 and EGFR are homologous membrane-bound receptors with tvrosine kinase activity which are expressed in many fetal and adult epithelia and are thought to play a role in the growth and differentiation of these normal tissues (Press et al.. 1990: Suda et alt. 1990; Madtes, 1993) . Overexpression of erbB-2 and EGFR has been identified in a variety of epithelial tumours and has been extensively studied in breast and lung cancer. In lung adenocarcinomas, erbB-2 overexpression relative to normal alveolar lung tissue has been found to correlate with a worse prognosis . EGFR overexpression in conjunction with autocrine ligand expression may also be associated with a worse prognosis in lung adenocarcinoma (Tateishi et al.. 1990 : Diattadi et al.. 1991 : Pavelic et al., 1993 : Veale et al.. 1993 . The association between overexpression of erbB-2 and EGFR with poor prognosis suggests that their overexpression may contribute to lung adenocarcinoma tumorigenesis and metastatic potential.
Despite the association with expression and poor prognosis, the exact role that erbB-2 or EGFR overexpression plays in lung adenocarcinoma development remains unclear. Malignant transformation by transfection of the EGFR alone has not yet been demonstrated, but it can induce mitogenesis in vitro after binding either EGF or transforming growth factor a (TGFa) (Velu et al., 1987; Di Marco et al.. 1989) . The transfection and overexpression of erbB-2 can confer tumorigenicity on immortalised fibroblasts (Chazin et al., 1992) but is insufficient to induce malignant transformation in transfected immortalised human bronchial epithelial cells (Noguchi et al.. 1993) or in transgenic mice (Stocklin et al.. 1993) . However. transfection and overexpression of erbB-2 have been show%n to enhance lung cancer cell metastatic potential (Yu et al.. 1994 ). It appears that erbB-2 and EGFR overexpression contributes to. but may be insufficient for, tumorigenesis in lung adenocarcinoma.
Signal regulation and tumorigenesis of erbB-2 and EGFR are dependent on their tyrosine kinase activity (Segatto et al., 1990) . ErbB-2 and EGFR are thought to interact by transphosphorylation via heterodimer formation, resulting in enhanced ligand affinity (Kokai et al., 1988; Connelly and Stern, 1990; Wada et al., 1990) . Expression of both receptors in a tumour cell may allow interaction between the two receptor types, modifying signal transduction in a way that could contribute to tumorigenesis. We hypothesise that erbB-2 and EGFR coexpression may provide a cooperative growth stimulus and therefore would be a selected characteristic of lung adenocarcinomas. This study was undertaken to establish the frequency of erbB-2 and EGFR coexpression in lung adenocarcinomas. In addition. established lung adenocarcinoma cell lines were used to examine the potential role of erbB-2 and EGFR in lung tumorigenesis by determining the expression of these receptors. their steady-state activation status and the effect of erbB-2 and EGFR ligand-mediated activation on cell growth. Immunoprecipitation Western blots were performed in a similar fashion except that cells or tissue membrane protein was incubated in primary antibody (polyclonal erbB-2) for 2 h. and then incubated in 50 ytL of protein A -agarose (Sigma) for 1 h. Protein A beads were then spun out, the precipitate resuspended. and gels and blots were prepared as described above.
Materials and methods

Human tissues
Growth assays
Cell lines were plated at low density using three 60-mm plates for each experimental group and then incubated in F 12 Ham's with 10% FBS overnight. Three plates were then counted to determine initial plating density (time zero). The F12 Ham's with 10% FBS was then removed and triplicate plates were treated with one of the following: F12 10% FBS.
SFM (serum-free medium). SFM plus 10 ng ml-' NDF P3 (a generous gift from Amgen. Thousand Oaks. CA. USA). (Figure 2b) . These results are consistent with EGFR protein expresson in bronchiolar epithelium, w the highest expression is present in the prolferatng basal cells (Figure le) .
Autocrie ligand expression Tumour cells may maintain constant levels of the erbB-2 receptor protein, but the expression of autocrine lgands for erbB-2 and EGFR may be major determinants for receptor activation and cell growth. Thefore, lung adenocarcinoma cell lines A549, A427 and SKLU1 were evaluated by Northern blot analysis for the expression of NDF and TGF-4 mRNA, the ligands capable of activating erbB-2 and EGFR respUecively. A549 cells expressed abundant mRNA for both NDF and TGF.<a, while A427 expressed only small amounts of TGF-a mRNA (Figure 3a) . HT-29 colon cancer cells a '.# Ac'.t. f expressed abundant TGF-x mRNA and SKBR3 breast cancer cells expressed potentially truncated forms of TGF-x mRNA. Interestingly, expression of NDF mRNA was highest in rapidly dividing, subconfluent A549 cells, and decreased as cells became confluent (Figure 2b) . Similarly, treatment of A549 cell lines with growth-inhibitory concentrations of dexamethasone (Speirs et al., 1991; Croxtall et al., 1993 ) also inhibited NDF mRNA in a dose-dependent manner (Figure 3b) . The association between high NDF mRNA expresson and rapid cell growth would be consistent with NDF acting as an autocrine growth factor in these cells.
Activation of erbB-2 and EGFR If erbB-2 and EGFR are contributing to tumorigenesis in lung adenocaranomas it would be expected that these reptors would show evidence of activation. Activation of erbB-2 and EGFR in cell lnes and tumours was therefore assessed by xamining receptor tyrosne phosphorylation using a PY-20 antiphosphotyrosine antibody and Western blot analysis.
Tyrosne kinase activity is known to be assocated with autophosphorylation of these receptors (Segatto et al., 1990 ).
The SKBR3 breast cells served as a positive control. The A549 lung crcinoma cells and five primary lung adenocarcinoma specim were examined. Western blot analysis demonstrated a 185 kDa erbB-2 protein in the A549 ells and prinary tumours, however little corresponding phosphotyro staining of 185 kDa proteins was present ( Figure  4a ). The SKBR3 cells contained a strong 185 kDa staining band with both erbB-2 and PY-20 antibodsie, demonstrating high-level constitutive activation of erbB-2 in these cells. A 175 IDa protein corresponding to the size of the EGFR was detectd using an anti-EGFR antibody in three out of four tumours. Unlike the erbB-2 protein, the EGFR was associated with a corresponding phosphotyrosine staining band, or possibly a doublet band, at 175 kDa. To detrmine whether freezing and thawing of the primary tumours before preparing protein extracs affected phosphotyrosine staining, A549 cell pellets were frozen at -70-C, and phosphotyrosine stain- To examine further the factors affecting erbB-2 and EGFR activation in the three lung adenocarcinoma cell lines, the A549, A427 and SKLU-1 (not shown) were analysed using Western blots and compared with the breast cell lines MCF-10 and SUM52. All three lung adenocarcinoma cell lines expressed the erbB-2 protein at 185 kDa, but little basal level phosphotyrosine staining at 185 kDa was observed ( Figure  4b) This may be due to the lower level of total erbB-2 protein present in the lung cells. ErbB-2 and EGFR activation in the lung adenocarcinoma cell lines was therefore similar to that present in the primary tumours.
To determine if erbB-2 or EGFR phosphotyrosine staining could be enhanced above basal levels, lung cell lines were treated with NDF and/or EGF. NDF treatment of A549 and A427 resulted in a slight increase in the phosphotyrosine staining of the 185 kDa band corresponding to the erbB-2 protein (Figure 5a ). This increase was much less than that seen in the breast cell line MCF1O, which had marked enhancement of the 185 kDa phosphotyrosine band following NDF treatment (Figure 5a ). Treatment of A549 cells with the antibody Tab-250, which has erbB-2 ligand-like properties in some cells, did not increase PY-20 staining of erbB-2. Addition of EGF to A549 cells did increase PY-20 phosphotyrosine staining associated with EGFR, as compared with either NDF treatment or under serum-free conditions ( Figure  5b ). Treatment with both NDF and EGF did not increase the extent of PY-20 staining of either the 175 kDa EGFR or the 185 kDa erbB-2 bands over that observed with either factor alone.
Growth of cells with NDF and EGF treatment A549 cells grown in SFM demonstrated a 14-fold increase in cell number after 1-week ( Figure 6 ). This suggests that these cells produce autocrine growth factors, and thus is consistent with the presence of TGF-a and NDF mRNA expressed in these cells (Figure 3a) . A427 cells grown in SFM demonstrated a 5-fold increase in cell number after 1 week (data not shown). The increased autocrine ligand expression in A549 cells corresponded with greater growth under serum-free conditions observed with these cells as compared with A427 cells (Figure 3a) 
Dosi
Overexpression without gene amplification of erbB-2 and EGFR has been described in a subset of lung adenocarcinomas (Slamon et al., 1989; Kern et al., 1990; Rusch et al., 1993) . In vitro studies suggest that erbB-2 and EGFR may interact through heterodimer formation or transphosphorylation (Kokai et al., 1988; Wada et al., 1990) . In breast cancer, erbB-2 and EGFR coexpression correlates with a poor prognosis (Osaki et al., 1992) , and amplification of these genes is more commonly observed. Information that these receptors may interact to contnibute to tumorigenesis led us to evaluate their coexpression in primary lung adenocarcinomas. Interestingly, all 43 (100%) lung adenocarcinoma tumours examined expressed erbB-2 protein, and 36 (83%) of these also expressed EGFR protein. All three lung adenocarcinoma cell lines examined also expressed both receptors. ErbB-2 and EGFR coexpression is therefore characteristic of most lung adenocarcinomas. The frequency of erbB-2 and EGFR coexpression reported in this study is higher than previously reported (Scagliotti et al., 1993) , possibly reflecting the enhanced sensitivity from using frozen rather than paraffin sections (Press et al., 1994 (Figure 3a) , ligands potentially capable of activating erbB-2 and EGFR respectively, only low-level erbB-2 activation is detected. Treatment of A549 and A427 cells with NDF increased the phosphotyrosine staining of the 185 kDa erbB-2 band in these cells, indicating that the receptors can be activated, however the level of activation was always less than that observed in the breast cell lines. Thus erbB-2 activation in lung adenocarcinoma tumours and cell lines is distinctly different from that of breast tissue. MCF1O benign mammary epithelial cells have low basal-level activation of erbB-2 similar to lung adenocarcinomas, but demonstrate a much greater capacity for activation by NDF. The SUM52 breast cancer cell line, which overexpresses erbB-2 protein without gene amplification, demonstrates greater basal-level activation of erbB-2 than is seen in lung adenocarcinoma cells. Amplification of erbB-2 in SKBR3 is associated with constitutive activation of greatly overexpressed erbB-2 protein. Amplification of erbB-2 expression is present in up to 30% of breast cancers and is associated with a worse patient prognosis independent of stage (Slamon et al., 1987) , possibly related to constitutive activation of erbB-2 tyrosine kinase. These differences between the lung and breast systems may relate to the absolute amounts of erbB-2 expressed, or may be related to the absence or presence of co-factors necessary for the activation of erbB-2 by NDF, such as erbB-3 or erbB4 (Akita et al.. 1994; Plowman et al., 1994) or cell specific factors (Peles et al., 1993) . We are currently examining whether the lung adenocarcinoma cells express either erbB-3 or erbB-4. It appears, therefore, that the role of erbB-2 in lung tumorigenesis differs from that of breast in both the frequency of amplification with constitutive activation and the capacity to be activated by NDF.
Growth assays of A549 and A427 demonstrate the capacity of these cells to grow under serum-free conditions. Autocrine growth factors NDF and TGF-a, produced by both lines, probably play a contributory role in their serumfree growth. Treatment of A549 and A427 with NDF further enhanced activation and stimulated cell growth above that of serum-free medium, demonstrating functional yet low-level activation in these cells. The relatively greater activation of EGFR relative to erbB-2 in both the lung cell lines and primary tumours, as demonstrated by Western blot staining for phosphotyrosine, may suggest that expression of erbB-2 may facilitate EGFR activation. ErbB-2 and EGFR are thought to interact by transphosphorylation via heterodimer formation, resulting in enhanced ligand affinity for the EGFR (Kokai et al., 1988; Connelly et al., 1990; Wada et al., 1990) . A549, interestingly, demonstrated an additive growth stimulus with NDF and EGF, suggesting a cooperative role between erbB-2 and EGFR, one that may exist in tumours coexpressing these receptors. Other transforming characteristics such as p53 and K-ras mutations are present in these cell lines (Lehman et al., 1991) , potentially contributing to their serum-free growth. Similarly, primary lung adenocarcinomas also contain alterations such as p53 and K-ras mutations (Bongiorno et al., 1994) , which may affect cell growth, invasive and metastatic properties. ErbB-2 and EGFR expression may therefore provide a cooperative ligand-dependent growth stimulus to bronchial epithelial cells, which acquire other critical genetic changes necessary for lung tumorigenesis.
